BLOG / 🇮🇳 India / index intelligence · · daily

BSE FMCG Sector Regulatory Filings — November 10, 2026

India BSE FMCG

By Gunpowder Editorial ·

7 medium priority 7 total filings analysed

Executive Summary

The India BSE FMCG digest for 2026-11-10 is dominated by Q2 FY27 operating updates from Emami and Dabur, both showing a two-speed consumption recovery: strong volume-led domestic growth offset by margin pressure and international disruptions.

Emami delivered 36% consolidated revenue growth (24% like-to-like) with 43% domestic volume growth, but gross margin contracted 520 bps and PAT fell 3% YoY on tax normalization. Dabur posted 11.6% consolidated growth with India FMCG up 10.7% (5.5% volume, 5.2% price) and international up 20%, marking its second consecutive quarter of double-digit revenue growth and fourth of double-digit PAT growth, though healthcare grew only 6.9% and India standalone margin diluted 10 bps. A clear sector theme is premiumization and distribution transformation: Dabur's premium portfolio rose from 17% to 20% of revenue growing at 4X the overall rate, Project Saksham cut distributors 43% while doubling throughput, and Project Samriddhi delivered INR115+ crores in savings. Management self-assessment is candidly mixed — Dabur rated itself 'red' on strategic M&A and 'amber' on core brand investment with media spend below commitment, a potential forward growth risk. Governance and event flow is heavy: Colgate-Palmolive and Radico Khaitan both have institutional investor meetings on November 16-18, 2026 (JM Financial India Xchange, CLSA India Forum, 360 One Trinity Asia), while Radico faces a DRI customs seizure of ~INR2.64 crore tied to an India-UK FTA tariff classification dispute. Dabur's liquidation of nil-contribution subsidiary Atlanta Body and Health Products is immaterial but signals ongoing portfolio pruning. No insider trading, dividend, buyback, or M&A transaction data was present in the enriched filings, limiting conviction signals; the actionable intelligence is concentrated in volume/margin divergence and the November 16-18 investor conference catalyst window.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Tracking the trend? Catch up on the prior BSE FMCG Sector Regulatory Filings digest from November 09, 2026.

Investment Signals (12)

  • Emami ↓ (BULLISH)
    ▲

    Consolidated revenue grew 36% YoY to INR1,088 crores, domestic sales up 49% with volume +43% and like-to-like growth of 24% — volume-led, not price-led, indicating genuine demand recovery

  • Emami ↓ (BULLISH)
    ▲

    Strategic investments grew 73% like-to-like and now contribute ~26% of domestic business, showing successful new-engine scaling beyond legacy brands

  • Emami ↓ (BULLISH)
    ▲

    EBITDA rose 25% to INR222 crores and PBT grew 29% to INR194 crores despite 520 bps gross margin contraction, demonstrating operating leverage and cost discipline

  • Dabur ↓ (BULLISH)
    ▲

    Q2 FY27 consolidated revenue grew 11.6% with India FMCG up 10.7% (volume 5.5%, price 5.2%) — second consecutive quarter of double-digit revenue growth and fourth consecutive quarter of double-digit PAT growth

  • Dabur ↓ (BULLISH)
    ▲

    International business grew 20% YoY, outpacing India FMCG's 10.7%, diversifying growth and offsetting domestic healthcare weakness

  • Dabur ↓ (BULLISH)
    ▲

    Premium portfolio rose from 17% to 20% of revenue and is growing at 4X the overall rate — a structural mix upgrade that should support margins over time

  • Dabur ↓ (BULLISH)
    ▲

    Project Saksham cut distributors by 43% while improving throughput 2X and distributor ROI 30%, and Project Samriddhi delivered over INR115 crores in savings — distribution and cost transformation is quantifiably working

  • Dabur ↓ (BULLISH)
    ▲

    General trade delivered its highest growth in about 19 quarters in Q2 FY27, with mid-single-digit growth for two consecutive quarters — a leading indicator of broad-based rural/urban trade recovery

  • International business declined 2% YoY, but excluding Nepal floods and Iraq it grew 6% — underlying international franchise is stable, with disruption transient [NEUTRAL/BULLISH]

  • Both scheduled for institutional investor meetings November 16-18, 2026 (JM Financial India Xchange, CLSA India Forum, 360 One Trinity Asia Singapore) — elevated institutional engagement often precedes guidance updates or strategic disclosures [NEUTRAL/CATALYST]

  • Dabur ↓ (NEUTRAL)
    ▲

    Liquidation of Atlanta Body and Health Products (nil turnover, nil net worth, no consideration) removes a dormant entity with zero financial impact — housekeeping, not a signal

  • ▲

    DRI seizure of ~INR2.64 crore goods is small relative to scale and company claims no material operational or financial impact; industry-wide FTA classification issue, not company-specific

Risk Flags (10)

  • Emami↓ [HIGH RISK]
    ▼

    Gross margin contracted 520 bps YoY, of which ~400 bps was raw-material cost inflation and the balance mix change — input-cost pressure is the dominant earnings risk

  • Emami↓ [HIGH RISK]
    ▼

    PAT fell 3% YoY to INR144 crores despite 36% revenue growth, due to normalization of effective tax rate after phasing out of fiscal benefits — tax tailwind is now gone, so future PAT growth must come from operations

  • Emami↓ [MEDIUM RISK]
    ▼

    International business declined 2% YoY due to Nepal floods and Gulf supply-chain disruptions — geographic concentration and external shocks remain unhedged

  • Dabur↓ [MEDIUM RISK]
    ▼

    Management rated itself 'red' on strategic M&A — inorganic growth engine is underdelivering 18 months into a 3-year vision, which could cap long-term growth optionality

  • Dabur↓ [MEDIUM RISK]
    ▼

    Management rated itself 'amber' on core brand investment, with media spend falling short of commitment — underinvestment in brand building could pressure volume growth in subsequent quarters

  • Dabur↓ [MEDIUM RISK]
    ▼

    Healthcare grew only 6.9% and management said it is 'not where we need it to be'; health supplements remain challenged — a key portfolio pillar is lagging

  • ▼

    India standalone margin diluted 10 bps YoY despite double-digit revenue growth — margin expansion is not yet accompanying the growth recovery [LOW/MEDIUM RISK]

  • Radico Khaitan↓ [MEDIUM RISK]
    ▼

    DRI seizure memos under Section 110 of the Customs Act issued November 06, 2026 for ~INR2.64 crore of goods; disclosure was delayed and only reported November 10, 2026 due to Diwali holidays — disclosure timing and potential escalation of the India-UK FTA tariff classification dispute bear monitoring

  • Sector-wide [MEDIUM RISK]
    ▼

    Both Emami and Dabur reported margin pressure (Emami -520 bps gross margin; Dabur India standalone -10 bps) alongside strong volume growth — the sector is buying growth with margin, a pattern that could compress earnings quality if input costs persist

  • Data gap
    ▼

    No insider trading, pledge, dividend, buyback, or M&A transaction data was present in any of the 7 enriched filings — absence of management conviction signals limits ability to validate the operating narratives [LOW RISK / MONITORING GAP]

Opportunities (10)

  • Emami↓ (OPPORTUNITY)
    ◆

    43% domestic volume growth with 24% like-to-like consolidated growth and 73% growth in strategic investments (now ~26% of domestic business) suggests a re-rating candidate if input-cost inflation moderates and gross margin recovers from the 520 bps compression

  • Emami↓ (OPPORTUNITY)
    ◆

    EBITDA +25% and PBT +29% despite margin headwinds shows operating leverage; once raw-material costs normalize, incremental revenue should flow disproportionately to PAT

  • Dabur↓ (OPPORTUNITY)
    ◆

    Premium portfolio at 20% of revenue growing 4X overall rate is a structural margin and mix upgrade story — watch for premium share crossing 25% as a re-rating trigger

  • Dabur↓ (OPPORTUNITY)
    ◆

    Project Saksham (distributors -43%, throughput 2X, ROI +30%) and Project Samriddhi (INR115+ crores savings) are quantifiable efficiency programs that could drive margin expansion in FY28

  • Dabur↓ (OPPORTUNITY)
    ◆

    General trade growth at a ~19-quarter high with two consecutive quarters of mid-single-digit growth signals a durable channel recovery — a leading indicator for volume acceleration

  • Dabur↓ (OPPORTUNITY)
    ◆

    International business +20% YoY provides a growth cushion and currency/geographic diversification while India healthcare (6.9%) recovers

  • ◆

    Investor meetings with JM Financial (Nov 16) and CLSA (Nov 18) create a near-term catalyst window for any strategic or demand commentary, even though no presentation is planned

  • Radico Khaitan↓ (CATALYST)
    ◆

    360 One Trinity Asia conference in Singapore (Nov 16-17) and CLSA India Forum (Nov 18) offer international investor engagement; if the DRI issue is contained, the stock could see relief

  • Dabur↓ (OPPORTUNITY)
    ◆

    Liquidation of dormant Atlanta entity simplifies the corporate structure with zero P&L impact — minor governance positive

  • Sector (OPPORTUNITY)
    ◆

    Volume-led growth (Emami +43%, Dabur +5.5%) in a still-recovering consumption environment suggests the FMCG volume cycle has turned; investors could position for operating leverage as input costs normalize

Sector Themes (6)

  • Volume-Led Recovery with Margin Sacrifice
    ◆

    Both reporting companies delivered strong volume growth (Emami +43% domestic volume, Dabur +5.5% India FMCG volume) but faced margin pressure (Emami -520 bps gross margin, Dabur India standalone -10 bps) — the sector is prioritizing share and volume over near-term margin, implying earnings quality depends on input-cost normalization

  • Premiumization as the Growth Engine
    ◆

    Dabur's premium portfolio rose from 17% to 20% of revenue growing at 4X the overall rate, and Emami's strategic investments grew 73% like-to-like to ~26% of domestic business — both companies are shifting mix toward premium/strategic segments, a sector-wide margin-accretive strategy

  • Distribution and Cost Transformation
    ◆

    Dabur's Project Saksham (distributors -43%, throughput 2X, ROI +30%) and Project Samriddhi (INR115+ crores savings) show FMCG companies are re-engineering go-to-market and cost structures — a template that could drive peer-wide efficiency gains

  • International as a Differentiator
    ◆

    Dabur's international business grew 20% YoY while Emami's declined 2% (but +6% ex-Nepal/Iraq) — international exposure is becoming a relative performance differentiator, with supply-chain disruptions (Nepal floods, Gulf) and trade agreements (India-UK FTA) creating both risk and opportunity

  • Candid Management Scorecards and Self-Governance
    ◆

    Dabur publicly rated itself 'red' on M&A and 'amber' on brand investment — a transparency trend that gives investors earlier warning on underperforming strategic pillars, improving forecastability

  • Heavy November Investor Engagement Window
    ◆

    Colgate-Palmolive, Radico Khaitan, and Dabur all had or have investor meetings in early-to-mid November 2026 (Dabur Nov 5; Colgate Nov 16/18; Radico Nov 16-18) — a concentrated catalyst window where guidance and demand commentary could move stocks

Watch List (8)

  • JM Financial India Xchange 2026 group meeting on November 16, 2026 at 09:00 IST and CLSA India Forum 2026 on November 18, 2026 at 09:00 IST — no presentation planned, but watch for any demand or pricing commentary

  • 360 One Capital Trinity Asia 2026 in Singapore on November 16-17, 2026 and CLSA 29th India Forum 2026 on November 18, 2026 — watch for management commentary on the DRI customs seizure and FTA tariff dispute

  • DRI seizure memos issued November 06, 2026 for ~INR2.64 crore of goods under Section 110 of the Customs Act; industry association engaged Ministry of Commerce on November 02, 2026 — monitor for escalation or resolution

  • 👁

    Healthcare growth of 6.9% and management's 'not where we need it to be' comment — watch for health supplements turnaround or further deceleration in Q3 FY27

  • 👁

    'Amber' rating on core brand investment with media spend below commitment — watch for catch-up ad spend in H2 FY27 and any volume impact

  • 👁

    'Red' rating on strategic M&A — watch for any inorganic announcement or strategy reset as the 3-year vision enters its second half

  • 👁

    Gross margin trajectory after 520 bps contraction (~400 bps raw material) — watch for input-cost commentary and pricing actions in the next quarter

  • 👁

    PAT decline of 3% YoY on tax normalization — watch whether operational growth can offset the loss of fiscal benefits in Q3 FY27

Filing Analyses (7)
Colgate Palmolive (India) Limited Analyst/Investor Meet neutral materiality 2/10

10-11-2026

Colgate-Palmolive (India) Limited disclosed under Regulation 30(2) of SEBI LODR that its officials will attend two institutional investor meetings in November 2026: the India Xchange 2026 group meeting hosted by JM Financial on November 16, 2026 at 09:00 a.m. IST, and the India Forum 2026 group meeting hosted by CLSA on November 18, 2026 at 09:00 a.m. IST, both in physical mode. The company explicitly stated that no presentation will be made and no unpublished price sensitive information will be shared. The filing contains no financial or operational data, so there are no positive or negative performance metrics to report.

  • · Scrip Code on BSE: 500830; NSE Symbol: COLPAL; Series: EQ
  • · Both meetings are group meetings conducted in physical mode
  • · Schedule is subject to change due to unavoidable circumstances and/or exigencies
  • · No presentation will be made at either meeting
  • · No unpublished price sensitive information will be shared with analysts/investors
  • · Filing signed and digitally dated November 10, 2026 at 13:01:03 +05:30
Colgate Palmolive (India) Limited Analyst/Investor Meet neutral materiality 2/10

10-11-2026

Colgate-Palmolive (India) Limited disclosed under Regulation 30(2) of SEBI LODR that its officials will attend two institutional investor meetings in November 2026: India Xchange 2026 hosted by JM Financial on November 16, 2026 at 09.00 a.m. IST, and India Forum 2026 hosted by CLSA on November 18, 2026 at 09.00 a.m. IST, both group meetings in physical mode. The company explicitly stated that no presentation will be made and no unpublished price sensitive information will be shared. The filing contains no financial or operational data, making it neutral in sentiment and low in financial materiality.

  • · Scrip Code on BSE: 500830; NSE Symbol: COLPAL; Series: EQ
  • · India Xchange 2026 meeting scheduled Monday, November 16, 2026 at 09.00 a.m. (IST), group meeting, physical mode
  • · India Forum 2026 meeting scheduled Wednesday, November 18, 2026 at 09.00 a.m. (IST), group meeting, physical mode
  • · Company stated no presentation shall be made at either meeting
  • · Schedule is subject to changes due to unavoidable circumstances and/or exigencies
  • · Filing signed and digitally dated 2026.11.10 13:01:03 +05'30'
Emami Limited Analyst/Investor Meet mixed materiality 8/10

10-11-2026

Emami reported Q2 FY27 consolidated revenue growth of 36% to INR1,088 crores, with domestic sales up 49% (volume +43%) and like-to-like consolidated growth of 24%. Strategic investments grew 73% like-to-like and contributed ~26% of domestic business, while international revenue declined 2% due to Nepal floods and Gulf supply-chain disruptions. Gross margin contracted 520 bps on input-cost inflation and mix change, but EBITDA rose 25% to INR222 crores and PBT grew 29% to INR194 crores; PAT fell 3% to INR144 crores on tax-rate normalization.

  • · International business declined 2% YoY; excluding Nepal and Iraq it grew 6%.
  • · Gross margin moderated 520 bps YoY, of which ~400 bps was raw-material cost and the balance mix change.
  • · PAT fell 3% YoY to INR144 crores due to normalization of effective tax rate after phasing out of fiscal benefits.
  • · Organized channels contribute 37% of domestic business; QuickCom is ~15% of digital sales.
  • · Strategic investments contributed ~26% of domestic business.
  • · Axiom and Brillare more than doubled sales; IncNut grew over 50%; The Man Company grew over 30%.
  • · Talc portfolio grew over 2X; BoroPlus grew in near 20s; Fair and Handsome double-digit; Navratna Oil in 30s; Kesh King high teens.
  • · Healthcare grew 11%, pain management in teens, OTC high teens, Medico single-digit.
  • · Full-year price increase was 5.5%.
  • · A&P spend guided at 18%-19% of sales for the full year.
  • · H2 FY27 total business growth guided at 18%-20%.
  • · Strategic investment revenue guidance raised to INR800-850 crores (run-rate implies INR1,000-1,100 crores).
  • · Buyback of 73 lakh shares worth INR281 crores completed; first interim dividend of INR5/share totaling INR214 crores approved.
  • · AI/data analytics platform expected to complete next quarter, with gains from April onwards.
Dabur India Limited Market Holiday neutral materiality 2/10

10-11-2026

Dabur India Limited disclosed that Atlanta Body and Health Products (Pty) Ltd., a wholly owned subsidiary of Dermoviva Skin Essentials Inc. (itself a step-down subsidiary via Dabur International Limited), has been liquidated/closed with effect from November 10, 2026 through voluntary liquidation/strike off. Atlanta contributed Nil turnover, revenue, income and net worth during the last financial year, and no consideration was received, so the dissolution has no material financial impact on Dabur.

  • · Atlanta was a wholly owned subsidiary of Dermoviva Skin Essentials Inc., which is a wholly owned subsidiary of Dabur International Limited, which in turn is a wholly owned subsidiary of Dabur India Limited.
  • · Closure was carried out by way of voluntary liquidation/strike off; no buyer was involved and the transaction is not a related party transaction.
  • · Disclosure made under Regulation 30 of SEBI (LODR) Regulations, 2015, referencing SEBI master circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.
  • · BSE Scrip Code: 500096; NSE Scrip Symbol: DABUR.
  • · Filing reference: SEC/SE/2026-27, signed and dated November 10, 2026.
Radico Khaitan Limited Analyst/Investor Meet neutral materiality 2/10

10-11-2026

Radico Khaitan Limited disclosed under Regulation 30 of SEBI Listing Regulations that its senior management will meet investors at two conferences: the 360 One Capital Trinity Asia 2026 conference in Singapore on 16-17 November 2026, and the CLSA 29th India Forum 2026 on 18 November 2026. The company stated it does not intend to discuss any Unpublished Price Sensitive Information during these meetings, and the investor presentation is available on its website. The filing contains no financial results or performance metrics.

  • · Investor meetings scheduled for 16-17 November 2026 (360 One Capital: Trinity Asia 2026, Singapore) and 18 November 2026 (CLSA 29th India Forum 2026)
  • · Company confirms it will not discuss Unpublished Price Sensitive Information during the meetings
  • · Meeting schedule is subject to change due to exigencies on the part of investor or Company
  • · Investor presentation available on company website (www.radicokhaitan.com)
  • · BSE Scrip Code: 532497; NSE Scrip code: RADICO
  • · CIN: L26941UP1983PLC027278
Radico Khaitan Limited Market Update negative materiality 5/10

10-11-2026

Radico Khaitan disclosed that the Directorate of Revenue Intelligence (DRI) issued seizure memos under Section 110 of the Customs Act, 1962 on November 06, 2026, covering goods valued at approximately INR 2.64 crore. The matter relates to an industry-wide customs tariff classification dispute over imported goods and preferential tariff treatment under the India-UK Free Trade Agreement, which the Industry Association has raised with the Ministry of Commerce. The Company claims no material operational or financial impact and expects early resolution, though the disclosure was delayed and only reported on November 10, 2026 due to Diwali holidays.

  • · Seizure memos were issued on Friday, November 06, 2026 at 19:21 P.M.
  • · Prior intimation referenced as letter no. RKL/SX/2026-27/76 dated October 27, 2026
  • · Industry Association discussed the issue with the Ministry of Commerce on November 02, 2026
  • · Company acknowledged delay in reporting was unintentional due to Diwali holidays
  • · Company states there is no material impact or disruption to business as of now
  • · Scrip Code: 532497 (BSE) and RADICO (NSE)
Dabur India Limited Analyst/Investor Meet mixed materiality 7/10

10-11-2026

Dabur India held an Analyst/Institutional Investor Meet on November 5, 2026, where India CEO Herjit Bhalla presented a scorecard on the 7 pillars of its 3-year vision (18 months in): premium portfolio rose from 17% to 20% of revenue and is growing at 4X overall rate, Project Saksham cut distributors by 43% while improving throughput 2X and distributor ROI 30%, and Project Samriddhi delivered over 115 crores in savings. However, the company rated itself 'red' on strategic M&A, 'amber' on core brand investment (media spend fell short of commitment) and health & wellness bets, while Q2 FY27 consolidated revenue grew 11.6% with India FMCG up 10.7% (volume 5.5%, price 5.2%) and international business up 20%; healthcare grew only 6.9% and India standalone margin diluted 10 bps.

  • · Q2 FY27 was the second consecutive quarter of double-digit revenue growth and fourth consecutive quarter of double-digit PAT growth
  • · Healthcare growth of 6.9% was described as a strong recovery, but management said it is 'not where we need it to be'; health supplements remain challenged while OTC and digestives grew in the teens
  • · General trade delivered its highest growth in about 19 quarters in Q2 FY27, with mid-single-digit growth for two consecutive quarters
  • · Premium portfolio is growing at 4X the overall rate and is margin accretive
  • · Digital now accounts for 43% of total media spend; influencer count increased over 3X
  • · 6 brands and 350 SKUs were rationalized under portfolio simplification
  • · Sesa will be integrated into Dabur starting December 1, with retrospective effect from April 1
  • · Dabur Ventures was formed in October 2025; RAS was its first investment earlier this year
  • · The company will initiate a medium-term strategic exercise for a 2031 plan, to be shared in the next 6 to 8 months
  • · Management reiterated full-year double-digit revenue growth guidance
  • · Incremental A&P investment of 150-200 bps planned under Ignite
  • · Targeted savings of INR 170-200 crore (1.5x the 115 crore achieved) to be reinvested
  • · Premiumization target of 23% of revenue over the next 18 months
  • · Retail Next program targets growth 1.5x the rest of general trade across 40,000 stores
  • · Rural direct reach target of over 100,000 geotagged villages
  • · No new global CEO will be appointed; international business continues to run independently under Mr. Narang's oversight

Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 7 filings

₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: BSE FMCG Sector Regulatory Filings

🇮🇳 More from India

View all →